NCT03077581

Brief Summary

This study was conducted to demonstrate post-abdominoplasty analgesic duration consequent to three different surgically infiltrated LA techniques; bilateral TAPB, bilateral RSB and subcutaneous infiltration using the same volume of 0.25% bupivacaine (40 ml). Pain score, total analgesic rescue requests and the total amount of systemic rescue analgesia used in the first postoperative day in addition to any detected postoperative complications were also recorded.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
48

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2017

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2017

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

March 3, 2017

Completed
10 days until next milestone

First Posted

Study publicly available on registry

March 13, 2017

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 5, 2017

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 15, 2017

Completed
Last Updated

March 13, 2017

Status Verified

March 1, 2017

Enrollment Period

3 months

First QC Date

March 3, 2017

Last Update Submit

March 7, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • morphine consumption (mg)

    postoperative morphine consumption in milligrams in the 1st 24 hours postoperatively

    up to 24 hours

Study Arms (3)

Transevrsus abdominus plane block group

ACTIVE COMPARATOR
Drug: Transevrsus abdominus plane block

Rectus sheath block group

ACTIVE COMPARATOR
Drug: Rectus sheath block

local infiltration group

ACTIVE COMPARATOR
Drug: local anesthesia infiltartion

Interventions

a blunt needle was advanced in the midaxillary line to reach the fascial layer between the internal oblique and transverse abdominis muscles detected by facial click sensation. The LA was slowly injected so as to detect any sign of toxicity or incorrect needle tip position (as resistance) requiring needle repositioning then TAPB was repeated on the opposite side.

Transevrsus abdominus plane block group

In RSB group, 2-3 cm from midline, about 3-5 cm above the umbilicus, the needle was advanced at right angle to the skin. The needle reaches the space between the posterior layer of the rectus sheath and rectus abdominis muscle detected by firm resistance of the posterior wall, The LA was slowly injected then the same steps were repeated on the other side.

Rectus sheath block group

40 mls of 0.255 bupivacaine will be infiltrated at skin incision

local infiltration group

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • all patients listed for abdominoplasty

You may not qualify if:

  • allergy to bupivacaine

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mansoura university

Al Mansurah, Dakahlia Governorate, Egypt

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer

Study Record Dates

First Submitted

March 3, 2017

First Posted

March 13, 2017

Study Start

March 1, 2017

Primary Completion

June 5, 2017

Study Completion

June 15, 2017

Last Updated

March 13, 2017

Record last verified: 2017-03

Locations